DBVT has been the topic of several other research reports. The Goldman Sachs Group lowered shares of DBV Technologies from a “neutral” rating to a “sell” rating in a research report on Friday, December 16th. Societe Generale raised shares of DBV Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, January 4th. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $5.63.
DBV Technologies Price Performance
NASDAQ DBVT opened at $1.56 on Tuesday. The company has a 50 day simple moving average of $1.41 and a 200-day simple moving average of $1.87. The firm has a market capitalization of $293.71 million, a price-to-earnings ratio of -2.84 and a beta of 1.29. DBV Technologies has a 52-week low of $1.08 and a 52-week high of $3.43.
Institutional Investors Weigh In On DBV Technologies
Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. grew its stake in shares of DBV Technologies by 16.5% in the first quarter. BlackRock Inc. now owns 687,341 shares of the company’s stock worth $1,093,000 after acquiring an additional 97,412 shares during the last quarter. ExodusPoint Capital Management LP acquired a new stake in DBV Technologies during the second quarter worth $352,000. BNP Paribas Arbitrage SNC boosted its stake in DBV Technologies by 203.3% during the third quarter. BNP Paribas Arbitrage SNC now owns 57,899 shares of the company’s stock worth $102,000 after buying an additional 38,812 shares in the last quarter. Envestnet Asset Management Inc. acquired a new stake in DBV Technologies during the third quarter worth $67,000. Finally, Two Sigma Investments LP boosted its stake in DBV Technologies by 80.9% during the third quarter. Two Sigma Investments LP now owns 35,920 shares of the company’s stock worth $64,000 after buying an additional 16,066 shares in the last quarter. Institutional investors and hedge funds own 18.37% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- Is Macau a Sinking Ship for Wynn Resorts?
- Don’t Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Pinterest is the Social Commerce Platform to Watch in 2023
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- Why Warner Bros Discovery Is the S&P’s Hottest Stock
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.